The BASE Study: Bicarbonate Administration to Stabilize Estimated Glomerular Filtration Rate (eGFR)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 194 participants.
Also called NCT02521181
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose other
- Phase
- Phase 3
- Enrolled
- 194 participants
- Registry
-
NCT02521181
-
- Other papers using this trial's data
- Oral Sodium Bicarbonate and Bone Turnover in CKD: A Secondary Analysis of the BASE Pilot Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02521181. Randomized; triple masking; primary purpose other. Start 2015-10 (actual); primary completion 2018-01 (actual). Results posted on 2020-10-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The BASE Study: Bicarbonate Administration to Stabilize Estimated Glomerular Filtration Rate (eGFR)
- Acronym
- BASE
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- Lower Dose Sodium Bicarbonate
- Intervention (Drug)
- Higher Dose Sodium Bicarbonate
- Intervention (Drug)
- Placebo
- Lead sponsor
- Jennifer Gassman, PhD
- Collaborator
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Collaborator
- The Cleveland Clinic
Record details
- Record id
cardio:ct-nct02521181- Content hash
c465ed8ed67b677ba6b77a33cfe08842faed6f19a20c2d9823b6fd5d53809357